Table 4. Comparison of primary and key secondary outcomes during the post intervention period dry season between study groups.

Outcomes	Placebo¶	SP bimonthly¶					AS+AQ bimonthly¶				AS+AQ monthly¶
	Episodes	Rate*	Episodes	Rate*	PE (95% CI)	p-value	Episodes	Rate*	PE (95% CI)	p-value	Episodes	Rate*	PE (95% CI)	p-value
Total OPD attendance	57	467.6	64	466.4	0.3 (−178.9 to 34.9)	0.422	47	362.8	22.4 (−124.2 to 50.6)	0.885	76	516.4	−10.4 (−301.7 to −4.3)	0.037
Malaria with any parasitaemia	10	3.7	14	5.0	−35.1 (−237.3 to 14.4)	0.870	15	5.8	−56.8 (−201.6 to 27.3)	0.720	7	2.5	32.4 (−125.9 to 55.8)	0.257
Malaria with high density (>7000 parasites /µl)	8	2.7	13	4.6	−70.0 (−574.9 to −4.6)	0.961	9	3.5	−29.6 (−395.5 to 15.4)	0.888	6	2.1	3.2 (−226.8 to 48.5)	0.435
Anaemia (Hb<8.0 g/dl)	9	4.6	6	3.5	23.4 (−105.6 to 75.4)	0.472	5	3.2	30.4 (−125.1 to 76.0)	0.410	3	1.6	65.2 (−263.0 to 91.0)	0.893
Malaria anaemia	7	2.4	5	1.8	25.0 (−133.1 to 77.2)	0.407	6	2.3	4.2 (−169.8 to 71.0)	0.171	3	1.1	54.4 (−606.0 to 89.5)	0.799
All cause admissions	3	2.3	3	2.5	−6.4 (−107.1 to 90.3)	0.961	6	2.7	−15.8 (−442.5 to 97.7)	0.938	5	2.4	− 3.8 (−155.9 to 93.5)	0.979
Malaria admissions	2	1.56	2	1.66	−6.4 (−159.8 to 93.4)	0.996	3	1.35	13.5 (−174.9 to 92.8)	0.918	2	0.97	37.8 (−513.3 to 97.9)	0.985

^*PE: protective efficacy = (1−rate ratio)^*100; rate ratio was ^¶adjusted for age at enrolment and bednet use